Skip to main content
Top
Published in: Clinical Journal of Gastroenterology 5/2021

01-10-2021 | Computed Tomography | Case Report

A liver metastasis 7 years after resection of a low-risk duodenal gastrointestinal stromal tumor

Authors: Masashi Inoue, Masayuki Shishida, Atsuhiro Watanabe, Ryujiro Kajikawa, Ryotaro Kajiwara, Hiroyuki Sawada, Ichiro Ohmori, Kazuaki Miyamoto, Masahiro Ikeda, Kazuhiro Toyota, Seiji Sadamoto, Tadateru Takahashi

Published in: Clinical Journal of Gastroenterology | Issue 5/2021

Login to get access

Abstract

Duodenal gastrointestinal stromal tumors (dGISTs) are rare, and a lack of consensus exists regarding their treatment, particularly for recurrent disease. We herein report a rare case of liver metastasis 7 years after resection of a low-risk duodenal gastrointestinal stromal tumor. A 45-year-old woman revealed positive fecal occult blood. Upper gastrointestinal endoscopy revealed a submucosal duodenal tumor with ulceration and oozing on the apex. Endoscopic ultrasound showed a hypoechoic mass originating in the submucosa. Contrast-enhanced abdominal computed tomography (CT) revealed a 30-mm hyper-vascular tumor in the duodenal bulb. The patient underwent partial resection of the duodenal bulb with distal gastrectomy, followed by Roux-en-Y reconstruction. Histopathological evaluation revealed a tumor comprised of spindle-shaped cells including 5 mitotic figures per 50 high-power fields. Immunohistochemical evaluation indicated that the tumor cells were positive for c-Kit and CD34 expression. The tumor was diagnosed as low-risk dGIST. Postoperative follow-up was continued, and 7 years later, CT revealed a 39-mm enhanced tumor in liver segment 4. The tumor was diagnosed as a metastatic liver tumor, and the patient underwent S4 partial hepatectomy. As a result of histological and immunohistochemical analysis, the tumor was diagnosed as a liver metastasis from dGIST. The patient has been receiving oral imatinib 400 mg daily and remains free of disease 5 years after her last surgery. Low-risk dGIST can metastasize relatively long after surgery. However, an excellent long-term prognosis may be achieved by combining complete resection and imatinib therapy in patients with recurrent liver metastases.
Literature
1.
go back to reference Goettsch WG, Bos SD, Breekveldt-Postma N, et al. Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study. Eur J Cancer. 2005;41:2868–72.CrossRef Goettsch WG, Bos SD, Breekveldt-Postma N, et al. Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study. Eur J Cancer. 2005;41:2868–72.CrossRef
2.
go back to reference Nilsson B, Bümming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era–a population-based study in western Sweden. Cancer. 2005;103:821–9.CrossRef Nilsson B, Bümming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era–a population-based study in western Sweden. Cancer. 2005;103:821–9.CrossRef
3.
go back to reference Agaimy A, Wunsch PH. Gastrointestinal stromal tumors: a regular origin in the muscularis propria, but an extremely diverse gross presentation. Langenbecks Arch Surg. 2006;391:322–9.CrossRef Agaimy A, Wunsch PH. Gastrointestinal stromal tumors: a regular origin in the muscularis propria, but an extremely diverse gross presentation. Langenbecks Arch Surg. 2006;391:322–9.CrossRef
4.
go back to reference Winfield RD, Hochwald SN, Vogel SB, et al. Presentation and management of gastrointestinal stromal tumors of the duodenum. Am Surg. 2006;72:719–22.CrossRef Winfield RD, Hochwald SN, Vogel SB, et al. Presentation and management of gastrointestinal stromal tumors of the duodenum. Am Surg. 2006;72:719–22.CrossRef
5.
go back to reference Sekine M, Imaoka H, Mizuno N, et al. Clinical course of gastrointestinal stromal tumor diagnosed by endoscopic ultrasound-guided fine-needle aspiration. Dig Endosc. 2015;27:44–52.CrossRef Sekine M, Imaoka H, Mizuno N, et al. Clinical course of gastrointestinal stromal tumor diagnosed by endoscopic ultrasound-guided fine-needle aspiration. Dig Endosc. 2015;27:44–52.CrossRef
6.
go back to reference Nishida T, Blay JY, Hirota S, et al. The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines. Gastric Cancer. 2016;19:3–14.CrossRef Nishida T, Blay JY, Hirota S, et al. The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines. Gastric Cancer. 2016;19:3–14.CrossRef
7.
go back to reference Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2003;33:459–65.CrossRef Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2003;33:459–65.CrossRef
8.
go back to reference Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diag Pathol. 2006;23:70–83.CrossRef Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diag Pathol. 2006;23:70–83.CrossRef
9.
go back to reference Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008;39:1411–9.CrossRef Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008;39:1411–9.CrossRef
10.
go back to reference Choi WH, Kim S, Hyung WJ, et al. Long-surviving patients with recurrent GIST after receiving cytoreductive surgery with imatinib therapy. Yonsei Med J. 2009;50:437–40.CrossRef Choi WH, Kim S, Hyung WJ, et al. Long-surviving patients with recurrent GIST after receiving cytoreductive surgery with imatinib therapy. Yonsei Med J. 2009;50:437–40.CrossRef
11.
go back to reference Bhattacharya S, Choudhury AK, Ravi S, et al. Six years survival on imatinib with no disease progression after diagnosis of metastatic duodenal gastrointestinal stromal tumour: a case report. J Med Case Rep. 2008;2:110.CrossRef Bhattacharya S, Choudhury AK, Ravi S, et al. Six years survival on imatinib with no disease progression after diagnosis of metastatic duodenal gastrointestinal stromal tumour: a case report. J Med Case Rep. 2008;2:110.CrossRef
12.
go back to reference Sakakura C, Hagiwara A, Soga K, et al. Long-term survival of a case with multiple liver metastases from duodenal gastrointestinal stromal tumor drastically reduced by the treatment with imatinib and hepatectomy. World J Gastroenterol. 2006;12:2793–7.CrossRef Sakakura C, Hagiwara A, Soga K, et al. Long-term survival of a case with multiple liver metastases from duodenal gastrointestinal stromal tumor drastically reduced by the treatment with imatinib and hepatectomy. World J Gastroenterol. 2006;12:2793–7.CrossRef
13.
go back to reference Cameron S, Schaefer IM, Schwoerer H, et al. Ten years of treatment with 400 mg imatinib per day in a case of advanced gastrointestinal stromal tumor. Case Rep Oncol. 2011;4:505–11.CrossRef Cameron S, Schaefer IM, Schwoerer H, et al. Ten years of treatment with 400 mg imatinib per day in a case of advanced gastrointestinal stromal tumor. Case Rep Oncol. 2011;4:505–11.CrossRef
14.
go back to reference Liu J, Zhang C, Hong D, et al. Percutaneous microwave ablation liver partition and portal vein embolization for planned hepatectomy due to large gastrointestinal stromal tumor metastases: a case report. Medicine (Baltimore). 2017;96:e8271.CrossRef Liu J, Zhang C, Hong D, et al. Percutaneous microwave ablation liver partition and portal vein embolization for planned hepatectomy due to large gastrointestinal stromal tumor metastases: a case report. Medicine (Baltimore). 2017;96:e8271.CrossRef
15.
go back to reference Hygum K, Wulff CN, Harsløf T, et al. Hypercalcemia in metastatic GIST caused by systemic elevated calcitriol: a case report and review of the literature. BMC Cancer. 2015;15:788.CrossRef Hygum K, Wulff CN, Harsløf T, et al. Hypercalcemia in metastatic GIST caused by systemic elevated calcitriol: a case report and review of the literature. BMC Cancer. 2015;15:788.CrossRef
16.
go back to reference Stratopoulos C, Soonawalla Z, Piris J, et al. Hepatopancreatoduodenectomy for metastatic duodenal gastrointestinal stromal tumor. Hepatobiliary Pancreat Dis Int. 2006;5:147–50.PubMed Stratopoulos C, Soonawalla Z, Piris J, et al. Hepatopancreatoduodenectomy for metastatic duodenal gastrointestinal stromal tumor. Hepatobiliary Pancreat Dis Int. 2006;5:147–50.PubMed
17.
go back to reference Ginori A, Scaramuzzino F, Marsili S, et al. Late hepatic metastasis from a duodenal gastrointestinal stromal tumor (29 years after surgery): report of a case and review of the literature. Int J Surg Pathol. 2015;23:317–21.CrossRef Ginori A, Scaramuzzino F, Marsili S, et al. Late hepatic metastasis from a duodenal gastrointestinal stromal tumor (29 years after surgery): report of a case and review of the literature. Int J Surg Pathol. 2015;23:317–21.CrossRef
18.
go back to reference DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231:51–8.CrossRef DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231:51–8.CrossRef
19.
go back to reference Dematteo RP, Heinrich MC, El-Rifai WM, et al. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol. 2002;33:466–77.CrossRef Dematteo RP, Heinrich MC, El-Rifai WM, et al. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol. 2002;33:466–77.CrossRef
20.
go back to reference Rubió-Casadevall J, Martinez-Trufero J, Garcia-Albeniz G, et al. Role of surgery in patients with recurrent, metastatic, or unresectable locally advanced gastrointestinal stromal tumors sensitive to imatinib: a retrospective analysis of the Spanish Group for Research on Sarcoma (GEIS). Ann Surg Oncol. 2015;22:2948–57.CrossRef Rubió-Casadevall J, Martinez-Trufero J, Garcia-Albeniz G, et al. Role of surgery in patients with recurrent, metastatic, or unresectable locally advanced gastrointestinal stromal tumors sensitive to imatinib: a retrospective analysis of the Spanish Group for Research on Sarcoma (GEIS). Ann Surg Oncol. 2015;22:2948–57.CrossRef
21.
go back to reference Gronchi A, Fiore M, Miselli F, et al. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg. 2007;245:341–6.CrossRef Gronchi A, Fiore M, Miselli F, et al. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg. 2007;245:341–6.CrossRef
22.
go back to reference Zaydfudim V, Okuno SH, Que FG, et al. Role of operative therapy in treatment of metastatic gastrointestinal stromal tumors. J Surg Res. 2012;177:248–54.CrossRef Zaydfudim V, Okuno SH, Que FG, et al. Role of operative therapy in treatment of metastatic gastrointestinal stromal tumors. J Surg Res. 2012;177:248–54.CrossRef
23.
go back to reference Hakimé A, Cesne AL, Deschamps F, et al. A role for adjuvant RFA in managing hepatic metastases from gastrointestinal stromal tumors (GIST) after treatment with targeted systemic therapy using kinase inhibitors. Cardiovasc Intervent Radiol. 2014;37:132–9.CrossRef Hakimé A, Cesne AL, Deschamps F, et al. A role for adjuvant RFA in managing hepatic metastases from gastrointestinal stromal tumors (GIST) after treatment with targeted systemic therapy using kinase inhibitors. Cardiovasc Intervent Radiol. 2014;37:132–9.CrossRef
24.
go back to reference Vassos N, Agaimy A, Hohenberger W, et al. Management of liver metastases of gastrointestinal stromal tumors (GIST). Ann Hepatol. 2015;14:531–9.CrossRef Vassos N, Agaimy A, Hohenberger W, et al. Management of liver metastases of gastrointestinal stromal tumors (GIST). Ann Hepatol. 2015;14:531–9.CrossRef
25.
go back to reference Sato S, Tsujinaka T, Masuzawa T, et al. Role of metastasectomy for recurrent/metastatic gastrointestinal stromal tumors based on an analysis of the Kinki GIST registry. Surg Today. 2017;47:58–64.CrossRef Sato S, Tsujinaka T, Masuzawa T, et al. Role of metastasectomy for recurrent/metastatic gastrointestinal stromal tumors based on an analysis of the Kinki GIST registry. Surg Today. 2017;47:58–64.CrossRef
Metadata
Title
A liver metastasis 7 years after resection of a low-risk duodenal gastrointestinal stromal tumor
Authors
Masashi Inoue
Masayuki Shishida
Atsuhiro Watanabe
Ryujiro Kajikawa
Ryotaro Kajiwara
Hiroyuki Sawada
Ichiro Ohmori
Kazuaki Miyamoto
Masahiro Ikeda
Kazuhiro Toyota
Seiji Sadamoto
Tadateru Takahashi
Publication date
01-10-2021
Publisher
Springer Singapore
Published in
Clinical Journal of Gastroenterology / Issue 5/2021
Print ISSN: 1865-7257
Electronic ISSN: 1865-7265
DOI
https://doi.org/10.1007/s12328-021-01464-w

Other articles of this Issue 5/2021

Clinical Journal of Gastroenterology 5/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.